Pune start-up gets US patent for delivering drugs to site-specific organs Press Release | March 6, 2023 Pune start-up gets US patent for delivering drugs to site-specific organs The patent was granted to Actorius Innovations and Research and its team that designed capsule shells using natural polymer to obtain a delayed release profile suitable for delivery of drugs to colon and rectum, said Dr Jayant Khandare, founder-director and Chief Scientific Officer of the start-up. Changes in lifestyle and food habits are leading to many colon related diseases including cancers, he said. Delivery of drugs to colorectal site is most challenging as the dosage forms have to prevent the early release of drug in stomach and intestine, he said. This patent (US Patent No. 11596607) is titled "Polymer based formulation for the release of drugs and bioactives at specific GIT sites". Khandare said the technology composition does not involve cumbersome tablet processing, coating and enteric or other polymers. It also reduces processing cost with increased patient compliance, he added. The start-up completed the bio equivalence study which was approved by Drugs Controller General of India (DCGI) in September 2020, Khandare said. Click the link below to read the full article. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover Lab Walkthrough Expert Insights | August 9, 2022 OncoDiscover Lab Walkthrough OncoDiscover Lab Walkthrough Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

OncoDiscover: affordable, rapid CTC platform for HNC patients in developing nations. Publications | June 4, 2019 ASCO 2019: Correlation of CTCs with disease progression in Indian oral cancer patients "OncoDiscover" is a fast, highly sensitive, and affordable (~$120) CTC nanosystem validated in 100 HNC patients to meet global medical needs. Background Liquid biopsy technologies are often unaffordable and unavailable in developing countries, despite these regions having the highest cancer burden and mortality rates. Current circulating tumor cell (CTC) technologies face significant clinical concerns, including non-specificity, low efficiency, high blood volume requirements, long turnaround times, and exorbitant costs (~$900–$1,400). We report an extremely low-cost, innovative nanosystem for the rapid enumeration of CTCs with higher specificity and efficiency. Methods We designed a nanosystem mediated by the conjugation of anti-EpCAM through a multi-reactive glutathione spacer, a carbon allotrope, and an amine-terminated dendrimer. The platform was evaluated for enhanced aqueous dispersibility and increased interaction with CTCs for rapid isolation and enumeration in 100 head and neck cancer (HNC) patients. These patients had various primary tumor sub-sites, including the oral cavity, larynx, hypopharynx, oropharynx, nasopharynx, salivary gland, and thyroid. The captured cells were immunostained, and the optimal fluorescence acquisition intensity was validated by accounting for CTCs with CK18 protein expression. Our method achieved the complete elimination of false-positive normal cell (NC) counts. The analysis was performed using only 1.5 ml of collected blood samples. Results The CTC distribution in the cohort study ranged from 1 to 85 cells per 1.5 ml of blood. In more than 80% of patients' CTCs, the quantitative estimation of anti-CK18 protein overexpression indicated an intensity approximately 10-fold higher than that of normal cells. Compared to treatment-naive, recurrent, and disease-free patients, the spread of CTC numbers across the clinical range appeared to be tight (close to the mean value). The CTC enumeration sensitivity linearity was ~99.2%, and the complete enumeration process time was under 3 hours per 1.5 ml of blood. Consequently, an efficient, rapid, and affordable CTC platform was designed and clinically validated. Conclusions The "OncoDiscover" liquid biopsy technology for CTC enumeration is poised to revolutionize the field due to its high sensitivity and affordability (~$120). It addresses a major unmet medical need in the developing world. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

PD-L1 expressing CTCs help monitor pancreatic cancer progression and MRD. Publications | November 25, 2024 ISLB 2024: Expression of Programmed Death - Ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients CTC detection with PD-L1 overexpression reveals aggressive pancreatic cancer and potential biomarker value for monitoring metastasis and disease progression. Introduction Pancreatic cancer shows a high mortality rate due to difficulties in early diagnosis and the absence of standardized guidelines for assessing suspicious pancreatic masses. Biomarkers such as carcinoembryonic antigen (CEA) and CA19-9 lack sufficient sensitivity and specificity for pancreatic cancer detection. While tissue biopsy provides a static signature of target protein expressions, including PD-L1, the enumeration and profiling of circulating tumor cells (CTCs) with cell surface markers can offer actionable targets for treatment. We present findings in pancreatic cancer where CTCs are associated with overexpression of PD-L1 as a dynamic marker for monitoring minimal residual disease (MRD) and disease progression, highlighting its role in the metastatic cascade. Methods Retrospectively, 50 pancreatic cancer patients were investigated for the presence of CTCs. Among them, 12 patients (24%) were in the early stage of disease, with ages ranging from 35 to 75 years. Sixty percent of patients were male (n = 30) and 40% were female (n = 20), while 76% (n = 38) were classified as late-stage cases. PD-L1 expression was evaluated using the approved OncoDiscover platform, which utilizes multi-component systems conjugated with anti-EpCAM antibodies on magnetic nanoparticles. CTC enumeration was performed using CD45–, EpCAM+, DAPI+, and CK18+ markers in 1.5 ml of peripheral blood. Functional assays assessed PD-L1 overexpression on CTCs using automated motorized Zeiss fluorescence microscopy. The sensitivity of the CTC and PD-L1 assay had been previously evaluated in other solid cancers. Results Out of 50 pancreatic cancer patients, 74% (n = 37) had at least one detectable CTC. Among these patients, 51% (n = 19) had one CTC, 30% (n = 11) had two CTCs, 14% (n = 5) had three CTCs, and 5% (n = 2) had four CTCs. The mean number of CTCs and clusters was 1.28 and 0.16, respectively. Additionally, 92% (n = 34) of patients demonstrated PD-L1 expression on CTCs. CTC clusters were observed in 19% of patients (n = 7). The mean PD-L1 expression on CTCs was 1.14. Conclusions CTCs with PD-L1 overexpression strongly suggest poor prognosis, potentially linked to activation of the metastatic cascade through immune system evasion. Larger studies are required to validate whether PD-L1-positive CTCs can serve as a reliable biomarker for the diagnosis and management of pancreatic cancer. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Comprehensive ctDNA and CTC profiling predicts metastasis in early breast cancer. Publications | January 15, 2023 AACR 2023: Abstract PR007: Comprehensive ctDNA profiling reveals potential metastatic genomic signatures in treatment-naive early-stage breast cancer patients Comprehensive ctDNA profiling and CTC analysis in early-stage breast cancer identifies driver mutations to predict early metastasis. Background Genomic profiling has revolutionized precision oncology, impacting diagnosis, prognosis, and therapy decisions. Considering the high spatiotemporal diversity and heterogeneity of breast tumor-cell genomes, small-gene panels often fail to capture rare but important genomic alterations. Conversely, comprehensive ctDNA sequencing approaches enable the identification of under-characterized 'long-tailed driver' genomic alterations and capture intra- and inter-metastatic heterogeneity. Here, we demonstrate the clinical utility of comprehensive genome profiling with higher sensitivity to predict the possibility of metastasis in early-stage breast cancer patients. Methods We retrospectively analyzed ctDNA and genomic DNA (gDNA) from FFPE samples, as well as circulating tumor cells (CTCs), in 10 treatment-naive, hormone-positive, and HER2-negative primary-stage breast cancer patients using the OncoIndx comprehensive 600-gene panel. The panel captures all important cancer-relevant genomic alterations, including tumor mutation burden (TMB), microsatellite instability (MSI), homologous recombination deficiency (HRD) prediction, and cfDNA tumor fraction (TF). CTCs were enumerated from 1.5 ml of blood using the OncoDiscover platform, approved by the Drug Controller General of India, using anti-EpCAM antibody-mediated immunomagnetic nanoparticles. CTCs were confirmed for cytokeratin 18+ and DAPI+ markers, and the absence of CD45. Results The comprehensive genomic profile obtained from ctDNA and gDNA from the FFPE of early-stage breast cancer patients predominantly exhibited the presence of alterations in PIK3CA and ESR1 signaling pathways. PIK3CA mutations were present in 77% and 44% of baseline ctDNA and gDNA samples, while ESR1 mutations were present in 44% and 22% of baseline ctDNA and gDNA, respectively. In addition, we observed about 70% additional driver mutations in ctDNA samples, suggesting the shedding of ctDNA together with CTCs (80% positive) as a likely positive biomarker of metastasis. About 50% of the patients showed higher TMB and HRD. Notably, TF representing ctDNA varied between 13% to 27% in blood samples with a corresponding ploidy range of 2.9 to 4.7. Surprisingly, ~50% of the patient population matched the mutation profile of clinically confirmed metastatic patients. All the patients harboring potential metastatic driver alterations showed the presence of CTCs in peripheral blood. Conclusions Comprehensive ctDNA genomic profiling showed potential metastasis-driving alterations, suggesting the role of ctDNA-based liquid biopsy to predict metastasis in early breast cancer patients. We observed enhanced TF at the time of diagnosis, possibly due to the presence of distant metastasis, high disease burden, and aggressive tumor biology. Our results suggest that ctDNA dynamics at the time of disease presentation can predict early metastasis and may demonstrate the divergent response of tumor heterogeneity to treatment in early-stage breast cancer. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Combined CTC and ctDNA analysis improves monitoring of metastatic colorectal cancer. Publications | October 17, 2025 Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients. Background Combined analysis of biomarkers such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) overexpressing tumorigenic proteins offers insight into evolving genotypic transitions from primary tumors that lead to metastasis in distant organs. We report the comparative distribution of CTCs and ctDNA genomic profiling in patients stratified as primary colorectal cancer (CRC) patients alone and those with metastasis progression in the liver, lung, and lymph nodes. Methods Retrospectively, we analyzed 218 patients with primary CRC (n = 153; male n = 93 and female n = 60). Metastasis was accounted for in 65 patients, namely liver (n = 27), lung (n = 8), and lymph nodes (n = 30). A total of 285 peripheral blood samples (218 baseline and 67 follow-up) were analyzed for the distribution of CTCs and ctDNA with driver mutations. CTCs expressing PD-L1 were evaluated using the CDSCO-approved OncoDiscover platform using 1.5 ml of blood. CTCs were enumerated based on EpCAM+, CK18+, DAPI+, and CD45– markers using a Zeiss automated fluorescence microscope. Further, the OncoIndx comprehensive NGS assay was performed using a 1080-gene panel. Results At baseline, 64.8% of primary CRC patients had ≥1 CTC (mean CTC distribution ~1.1), while 55.9% of patients had detectable ctDNA. In patients with metastasis (n = 65), the mean CTC distribution was 1.8. Higher CTC distribution was observed in liver metastasis (41.5%), lymph node involvement (46.2%), and lung metastasis (12.3%). A total of 71.7% of patients had detectable CTCs, among which 88.2% showed PD-L1 expression, while 61.3% of patients had detectable ctDNA. Concordance rates were 83.7% and 100% between the presence of CTCs and ctDNA in baseline and follow-up samples from patients with primary cancer, respectively. Furthermore, a strong correlation was observed between elevated CTC counts and the presence of ctDNA mutations in key oncogenes, including KRAS, EGFR, and BRAF. Conclusions Higher co-occurrence of ctDNA with CTCs at both baseline and follow-up highlights the need for monitoring disease progression and assessing treatment response. Thus, combined analysis of CTCs and ctDNA provides significant prognostic value in metastatic colorectal cancer. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Non-hemolytic adsorbents for toxin isolation, disease tracking & therapy efficacy. Patents | October 20, 2025 Non-hemolytic compositions and methods of use for recovering disease-causing toxic constituents in the blood A non-hemolytic adsorbent composition designed to isolate, quantify, and remove disease-causing toxic constituents from blood, supporting disease identification, monitoring, and therapeutic efficacy validation. Patent Details The present disclosure relates to non-hemolytic adsorbent compositions useful for isolating, enumerating, accounting, and removing the disease-causing toxic constituents in the blood. The said compositions are useful in identifying the disease, disease status, and validating the efficacy of the therapeutic treatment being administered for the treatment of the disease. Methods for isolating, enumerating, accounting, and removing disease-causing toxic constituents in the blood as well as monitoring the disease status and validating the efficacy of the therapeutic treatment being administered for the treatment of the disease are disclosed. Related patent documents US20210106742 WO/2021/074786 CA3154234 IN202044044657 View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Explore our Privacy Policy. Learn how your data is protected and securely managed with our Privacy Policy. Privacy Policy Date Updated: 03 March 2026 Actorius Innovations and Research Co. (“we,” “us,” or “our”) is committed to protecting your privacy. This Privacy Policy explains how we collect, use, disclose, and safeguard your personal information when you access or use our website at [https://www.actorius.com ] (“Site”). This policy is designed to comply with applicable U.S. privacy laws, including the California Consumer Privacy Act (CCPA) , as amended by the California Privacy Rights Act (CPRA) , and other relevant federal and state regulations. 1. Information We Collect We may collect the following categories of personal information: a. Personal Information Information that identifies, relates to, or could reasonably be linked to you, including: Full name Email address Phone number (optional) Organization or company name (optional) Professional details you choose to share Any other information voluntarily submitted via forms or inquiries b. Automatically Collected Information (Usage Data) When you use our Site, we may automatically collect: IP address Browser type and version Device type and operating system Pages visited and time spent Referring and exit URLs Device identifiers Approximate geolocation (based on IP) 2. How We Use Your Information We use collected information to: Operate, maintain, and improve our Site Personalize your experience Analyze user behavior and site performance Respond to inquiries and provide support Send communications (only with your consent where required) Ensure security and prevent fraud Comply with legal obligations We will not use your personal information for materially different purposes without notice. 3. Disclosure of Information We do not sell personal information. We may disclose your information in the following situations: To service providers (e.g., hosting, analytics, CRM tools) under contractual obligations To comply with legal requirements (court orders, subpoenas, regulatory requests) To protect rights, property, or safety of our company, users, or others In connection with a business transaction (e.g., merger, acquisition, asset sale) 4. Cookies and Tracking Technologies We use cookies and similar technologies to: Remember user preferences Analyze website traffic Improve functionality Deliver relevant content and marketing (where permitted) Depending on your location (e.g., California), you may have the right to opt out of certain tracking technologies. You can manage cookies through your browser settings. 5. Your Privacy Rights If you are a resident of certain U.S. states (such as California), you may have the following rights: Right to Know – Request details about personal data collected and used Right to Access – Request a copy of your personal data Right to Delete – Request deletion of your personal data Right to Correct – Request correction of inaccurate data Right to Opt-Out – Opt out of sale or sharing of personal data (if applicable) Right to Non-Discrimination – You will not be discriminated against for exercising your rights To exercise your rights, please contact us using the details below. We may need to verify your identity before processing requests. 6. Data Retention We retain personal information only as long as necessary to: Fulfill the purposes outlined in this policy Comply with legal obligations Resolve disputes and enforce agreements 7. Data Security We implement reasonable administrative, technical, and physical safeguards to protect your personal information. However, no system is completely secure, and we cannot guarantee absolute security. 8. Children’s Privacy Our Site is not intended for individuals under the age of 13. We do not knowingly collect personal information from children. If we become aware of such data collection, we will delete it promptly in accordance with the Children’s Online Privacy Protection Act (COPPA). 9. Third-Party Links Our Site may contain links to third-party websites. We are not responsible for their privacy practices. We encourage you to review their policies before providing any information. 10. Changes to This Privacy Policy We may update this Privacy Policy from time to time. Updates will be posted on this page with a revised “Last Updated” date. 11. Contact Us If you have any questions or wish to exercise your privacy rights, please contact us: Website: https://www.actorius.com/contact Email: info@actorius.com

Explore our Actorius Innovation's Terms & Conditions. Understand your rights and obligations with our comprehensive Terms & Conditions. Terms & Conditions Date Updated: 03 March 2026 Welcome to the official website of Actorius Innovations & Research Co. (“Company,” “we,” “us,” or “our”), accessible at [https://actorius.com ] (the “Website”). By accessing or using this Website, you agree to comply with and be bound by the following Terms and Conditions. Please review them carefully. 1. Acceptance of Terms By accessing, browsing, or using this Website, you confirm that you have read, understood, and agreed to these Terms and our Privacy Policy. 2. Use of the Website The content on this Website is provided for general informational and educational purposes only and may be updated without notice. You agree to: Use the Website only for lawful purposes Not misuse, disrupt, or attempt to gain unauthorized access Not infringe upon the rights of others Important: This Website does not provide medical advice. Any healthcare-related content, including information about therapeutic solutions such as OncoMetstat, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for medical decisions. 3. Intellectual Property Rights All content on this Website—including text, graphics, logos, images, software, and design—is owned by Actorius Innovations & Research Pvt. Ltd. or its licensors and is protected under U.S. and international intellectual property laws. You may not: Copy, reproduce, or distribute content Modify or create derivative works Use content for commercial purposes Without prior written permission. 4. Third-Party Links This Website may include links to third-party websites for convenience. We: Do not control or endorse third-party content Are not responsible for their privacy practices or terms Disclaim liability for any damages resulting from third-party use 5. Disclaimer of Warranties This Website is provided on an “as is” and “as available” basis. To the fullest extent permitted under applicable U.S. law, we disclaim: All warranties (express or implied), including merchantability and fitness for a particular purpose Any guarantee that the Website will be uninterrupted, secure, or error-free 6. Limitation of Liability To the maximum extent permitted by law, Actorius Innovations & Research Pvt. Ltd. shall not be liable for: Indirect, incidental, consequential, or punitive damages Loss of profits, data, or business opportunities Damages arising from use or inability to use the Website Some U.S. states do not allow certain limitations, so parts of this section may not apply to you. 7. Indemnification You agree to indemnify and hold harmless Actorius Innovations & Research Pvt. Ltd., its affiliates, officers, employees, and partners from any claims, damages, or expenses arising from: Your use of the Website Your violation of these Terms Your infringement of any third-party rights 8. Healthcare & Diagnostic Services Disclaimer Services referenced on this Website (including diagnostics, research, or analytics): May be subject to additional agreements and regulatory requirements Are not available in all jurisdictions May require physician involvement or authorization Where applicable, services handling health data may be governed by the Health Insurance Portability and Accountability Act (HIPAA) and related regulations. 9. Services, Payments, Refunds, and Cancellations Where services are offered: Terms will be specified at the time of engagement Due to the scientific and diagnostic nature of services, refunds may be limited or unavailable once processing begins Cancellation requests must be submitted in writing and are evaluated case-by-case 10. Privacy Your use of the Website is also governed by our Privacy Policy, which outlines how we collect and use personal data, including rights under laws such as: U.S. state privacy laws (e.g., CCPA/CPRA) HIPAA (where applicable) 11. Governing Law and Jurisdiction These Terms shall be governed by the laws of the United States and the State of [Insert State, e.g., Delaware or California], without regard to conflict of law principles. You agree that any disputes shall be resolved in the courts located in: [California, USA] However, if you access the Website from outside the U.S., you are responsible for compliance with local laws. 12. International Users This Website is operated from the United States but may be accessed globally. By using the Website, you acknowledge that: Your data may be transferred to and processed in the United States U.S. data protection laws may differ from those in your jurisdiction 13. Modifications to Terms We may update these Terms at any time. Changes become effective immediately upon posting. Continued use of the Website constitutes acceptance of the updated Terms. 14. Termination We reserve the right to suspend or terminate access to the Website at our discretion, without notice, for conduct that violates these Terms or applicable laws. 15. Contact Information If you have any questions regarding these Terms: Actorius Innovations & Research Co. Website: https://actorius.com Contact Page: https://actorius.com/contact Email: info@actorius.com

Dr. Jayant Khandare interview with Metro News Gujarat Press Release | August 9, 2022 Revolutionary OncoDiscover® Blood Test for Early Cancer Detection - Metro News Gujarat Dr. Jayant Khandare interview with Metro News Gujarat Watch Video Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Large study shows CTCs and clusters predict aggressive epithelial cancer progression. Publications | April 10, 2024 AACR 2024: Distribution prophecy of circulating tumor cell clusters in CTC populace patients of epithelial cancers Large-scale analysis of circulating tumor cells and clusters reveals their role in predicting aggressive epithelial cancers and treatment resistance. Background: The role of circulating tumor cells (CTCs) in metastatic cancers for predicting overall survival has been well established. The effectiveness of three- or six-month adjuvant therapy in colorectal cancer estimation has shown an association between CTCs and the emergence of resistant cell clones. The presence of CTC clusters indicates increased aggressiveness in epithelial cancers. However, the presence of CTC clusters has not been evaluated in large patient populations. Here, we demonstrate the distribution and prognostic significance of CTCs and CTC clusters in epithelial cancer patients. Methods: Retrospectively, blood samples from 3458 patients were analyzed for the presence and distribution of CTCs and CTC clusters using the DCGI-approved OncoDiscover platform, which uses an immunomagnetic multicomponent system mediated by an anti-EpCAM antibody. A total of 1.5 mL of peripheral blood was analyzed to capture cells and clusters from head and neck, breast, and lung cancer patients. The sensitivity, specificity, and accuracy of the OncoDiscover assay had been previously established. CTCs and clusters were identified using CK18 positive, DAPI positive, and CD45 negative staining with automated motorized fluorescence microscopy. CTC clusters were defined as the presence of two or more CTCs bound together. Results: Out of 3458 epithelial cancer patients, 65.52% (2262 patients) showed the presence of CTCs, with CTC numbers varying from 1–9 per 1.5 mL of blood. Meanwhile, 7.54% of patients showed CTC clusters, corresponding to 261 clusters. The total number of captured CTCs and clusters was 19,345, with a mean distribution of 5.59. Among these, CTCs accounted for 19,037 (98.41%), while clusters accounted for 308 (1.59%). The highest number of CTCs was observed in head and neck cancers (52.98%) and breast cancers (22.75%), followed by lung cancer (5.65%). In contrast, clusters were most frequently observed in breast cancers (26.95%), followed by lung cancer (16.23%). Conclusions: The frequency and distribution of CTCs and CTC clusters were evaluated in epithelial cancers. Patients with CTCs alone and those with both CTCs and CTC clusters represent a more aggressive disease state and a higher likelihood of disease progression. The effectiveness of adjuvant therapy in epithelial cancers may be estimated using CTC and cluster analysis, as their presence may indicate treatment resistance and the emergence of resistant cell clones. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Combined ctDNA and CTC profiling correlates with PET-CT in cancer progression monitoring. Publications | November 25, 2024 ISLB 2024: Comprehensive Analysis of ctDNA and CTCs Reveals Resistance signatures and Correlations with PET Scan Outcomes in Cancer Patients Integrated ctDNA and CTC analysis correlates with PET-CT outcomes to reveal treatment resistance and aggressive cancer progression. Introduction Liquid biopsy offers real-time insights into tumor dynamics. Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) stand out as promising biomarkers due to their potential to provide comprehensive information about tumor evolution, treatment response, and the emergence of resistance. Concordance between ctDNA, CTCs, and PET-CT scans holds immense promise in cancer management, including identifying treatment resistance and correlating with PET scan outcomes. Methods Retrospectively, 18 patients with progressive and/or metastatic disease undergoing treatment were monitored. Paired samples for ctDNA and CTCs were evaluated. NGS libraries were prepared using a hybridization-capture method based on the custom-designed OncoIndx 1080 CGP panel and deep sequenced on the Illumina NextSeq 2000 in paired-end mode (150 × 2). Variant calling was performed using the proprietary bioinformatics pipeline iCare. CTCs were isolated using the OncoDiscover platform possessing an anti-EpCAM antibody-based immunomagnetic system from 1.5 ml of blood. CTCs were confirmed with CK18+, PD-L1+, DAPI+, and CD45– markers. Results ctDNA analysis showed that every patient (100%, n = 18) had at least one actionable genomic finding. Among them, 44.44% (n = 8) had concurrent mutations in the BRCA1/2 and TP53 genes, and 87.5% (n = 7) of these patients also possessed detectable CTCs. A smaller subset, 11.11% (n = 2), showed driver mutations in the EGFR gene. The remaining patients exhibited mutations in genes including KRAS, PTEN, STK11, RB1, AR, KIT, MET, and CDKN2A. These molecular profiles correlated with treatment resistance and were consistent with PET scan results showing disease progression in 88.88% (n = 16) of patients. Only 11.11% (n = 2) of the cohort demonstrated therapeutic response in recent PET scans. Notably, the combination of BRCA1/2 and TP53 mutations, along with the presence of CTCs, was primarily observed in patients with advanced or metastatic aggressive disease. These co-occurring mutations were identified in ovarian, biliary duct, and breast cancers. Conclusions The concurrent presence of BRCA1/2 and TP53 mutations alongside CTCs suggests aggressive disease progression and metastasis across the patient group. Moreover, the molecular interplay between BRCA1/2 and TP53 mutations has been associated with resistance to PARP inhibitors. These findings emphasize the urgent need for longitudinal monitoring in patients with both BRCA1/2 and TP53 mutations coupled with CTC detection. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe